Results 11 to 20 of about 222,830 (234)

Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes

Nature Communications, 2021
Progress in precision medicine is limited by insufficient knowledge of transcriptomic or proteomic features in involved tissues that define pathobiological differences between patients.
Bradley A. Maron, Rui-Sheng Wang, Sergei Shevtsov, Stavros G. Drakos, Elena Arons, Omar Wever-Pinzon, Gordon S. Huggins, Andriy O. Samokhin, William M. Oldham, Yasmine Aguib, Magdi H. Yacoub, Ethan J. Rowin, Barry J. Maron, Martin S. Maron, Joseph Loscalzo   +14 more
doaj   +2 more sources

Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice

Nature Network Boston, 2023
Dominant missense pathogenic variants in cardiac myosin heavy chain cause hypertrophic cardiomyopathy (HCM), a currently incurable disorder that increases risk for stroke, heart failure and sudden cardiac death.
D. Reichart, Gregory A. Newby, H. Wakimoto, M. Lun, J. Gorham, Justin J. Curran, Aditya Raguram, D. DeLaughter, D. Conner, Júlia D C Marsiglia, Sajeev Kohli, Lukas Chmatal, D. Page, N. Zabaleta, L. Vandenberghe, David R. Liu, J. Seidman, C. Seidman   +17 more
semanticscholar   +1 more source

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy

European Heart Journal, 2023
Graphical Abstract Graphical Abstract The path to treatment of obstructive hypertrophic cardiomyopathy. (Top left) Haemodynamic observations demonstrated. Left ventricular (LV) obstruction and symptoms related to LV hypertrophy.
E. Braunwald, S. Saberi, T. Abraham, Perry M. Elliott, I. Olivotto   +4 more
semanticscholar   +1 more source

Hypertrophic Cardiomyopathy

Journal of Cardiovascular Development and Disease, 2023
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy resulting from a mutation in one of several cardiac sarcomeric proteins [...]
Asra K. Butt, Deya Alkhatib, Issa Pour-Ghaz, Sakiru Isa, Omar Al-Taweel, Ifeoma Ugonabo, Neeraja Yedlapati, John Lynn Jefferies   +7 more
openaire   +3 more sources

Expanding the deep-learning model to diagnosis LVNC: Limitations and trade-offs [PDF]

Computer Methods in Biomechanics and Biomedical Engineering: Imaging & Visualization. 2024, 2023
Hyper-trabeculation or non-compaction in the left ventricle of the myocardium (LVNC) is a recently classified form of cardiomyopathy. Several methods have been proposed to quantify the trabeculae accurately in the left ventricle, but there is no general agreement in the medical community to use a particular approach.
arxiv   +1 more source

Hypertrophic cardiomyopathy

IJC Heart & Vasculature, 2020
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. The disease is characterized by marked variability in morphological expression and natural history, ranging from asymptomatic to heart failure or sudden cardiac death. Left ventricular hypertrophy and abnormal ventricular configuration result in dynamic left ventricular ...
Murillo de Oliveira Antunes, Thiago Luis Scudeler   +1 more
openaire   +4 more sources

Altered Cardiac Energetics and Mitochondrial Dysfunction in Hypertrophic Cardiomyopathy

Circulation, 2021
Supplemental Digital Content is available in the text. Background: Hypertrophic cardiomyopathy (HCM) is a complex disease partly explained by the effects of individual gene variants on sarcomeric protein biomechanics. At the cellular level, HCM mutations
Sara Ranjbarvaziri, Kristina B. Kooiker, M. Ellenberger, G. Fajardo, Mingming Zhao, A. V. Vander Roest, R. A. Woldeyes, Tiffany T Koyano, R. Fong, Ning Ma, Lei Tian, G. Traber, F. Chan, J. Perrino, Sushma Reddy, Wah Chiu, Joseph C. Wu, Joseph Y. Woo, K. Ruppel, J. Spudich, M. Snyder, K. Contrepois, D. Bernstein   +22 more
semanticscholar   +1 more source

Machine Learning Methods for Identifying Atrial Fibrillation Cases and Their Predictors in Patients With Hypertrophic Cardiomyopathy: The HCM-AF-Risk Model [PDF]

CJC Open, Volume 3, Issue 6, June 2021, Pages 801-813, 2021
Hypertrophic cardiomyopathy (HCM) patients have a high incidence of atrial fibrillation (AF) and increased stroke risk, even with low risk of congestive heart failure, hypertension, age, diabetes, previous stroke/transient ischemic attack scores. Hence, there is a need to understand the pathophysiology of AF and stroke in HCM.
arxiv   +1 more source

Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy

European Heart Journal, 2021
Aims Childhood-onset hypertrophic cardiomyopathy (HCM) is far less common than adult-onset disease, thus natural history is not well characterized. We aim to describe the characteristics and outcomes of childhood-onset HCM.
N. Marston, Larry Han, I. Olivotto, S. Day, E. Ashley, M. Michels, A. Pereira, J. Ingles, C. Semsarian, D. Jacoby, S. Colan, J. Rossano, S. Wittekind, J. Ware, S. Saberi, A. Helms, Carolyn Y. Ho   +16 more
semanticscholar   +1 more source

Identifying Ventricular Arrhythmias and Their Predictors by Applying Machine Learning Methods to Electronic Health Records in Patients With Hypertrophic Cardiomyopathy(HCM-VAr-Risk Model) [PDF]

The American Journal of Cardiology, Volume 123, Issue 10, 15 May 2019, Pages 1681-1689, 2021
Clinical risk stratification for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HC) employs rules derived from American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines or the HCM Risk-SCD model (C-index of 0.69), which utilize a few clinical variables.
arxiv   +1 more source